Hemanext
Hemanext is a global biomedical technology pioneer in transfusion medicine, committed to optimizing the therapeutic impact and value of blood to the healthcare system. Focused on the study of hypoxically stored RBCs, their research aims to significantly improve the quality of stored RBCs worldwide, striving to deliver innovations that improve patient care and transform RBCs during storage.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Red blood cell processing and hypoxic storage system
Processing and storage system that reduces oxygen and carbon dioxide levels in the red blood cell storage environment to produce hypoxically stored, leukocyte‑reduced red blood cell units intended for refrigerated storage and transfusion; includes validated storage parameters for specified unit formats.
Red blood cell processing and hypoxic storage system
Processing and storage system that reduces oxygen and carbon dioxide levels in the red blood cell storage environment to produce hypoxically stored, leukocyte‑reduced red blood cell units intended for refrigerated storage and transfusion; includes validated storage parameters for specified unit formats.
Services
Design and operational support for clinical and post-market studies assessing safety and efficacy of processed and stored red blood cell products, including randomized and post-market safety study designs.
Support for regional market entry through distributor agreements, training, and supply relationships with hospitals and blood establishments.
Development and delivery of clinician-facing educational content and sponsored forums (webinars, recorded sessions, in-person symposiums) on storage science, transfusion outcomes, and product implementation.
Facility-based production and process development for blood processing and storage systems, including manufacturing scale-up, operations management, and local production oversight.
Engagement of external clinical advisors and key opinion leaders to provide strategic input on clinical development, research priorities, and medical affairs activities.
Support for scientific conference presence including exhibit booths, presentations, and sponsored forum sessions to engage clinical and industry stakeholders.
Design and operational support for clinical and post-market studies assessing safety and efficacy of processed and stored red blood cell products, including randomized and post-market safety study designs.
Support for regional market entry through distributor agreements, training, and supply relationships with hospitals and blood establishments.
Development and delivery of clinician-facing educational content and sponsored forums (webinars, recorded sessions, in-person symposiums) on storage science, transfusion outcomes, and product implementation.
Facility-based production and process development for blood processing and storage systems, including manufacturing scale-up, operations management, and local production oversight.
Engagement of external clinical advisors and key opinion leaders to provide strategic input on clinical development, research priorities, and medical affairs activities.
Support for scientific conference presence including exhibit booths, presentations, and sponsored forum sessions to engage clinical and industry stakeholders.
Expertise Areas
- Transfusion medicine and red blood cell biology
- Clinical trial management for blood products
- Blood product processing and hypoxic storage engineering
- Regulatory strategy and market access for novel blood products
Key Technologies
- Hypoxic storage (oxygen and CO2 reduction) for cellular products
- Leukoreduction processing
- Refrigerated cold-chain storage at 1–6°C
- Metabolomics
News & Updates
Hemanext participated in the AABB Science & Innovation Forum in November 2023, featuring faculty members such as Paul Ness, Angelo D’Alessandro, Steven Spitalnik, and Susanne Marschner, discussing advancements in transfusion medicine.
Hemanext showcased its innovations at the 2022 AABB Annual Meeting held virtually in November 2022.
Hemanext's RBC Processing & Storage System is CE Marked for the processing and storage of leukocyte-reduced RBCs.
Hemanext participated in the AABB Science & Innovation Forum in November 2023, featuring faculty members such as Paul Ness, Angelo D’Alessandro, Steven Spitalnik, and Susanne Marschner, discussing advancements in transfusion medicine.
Hemanext showcased its innovations at the 2022 AABB Annual Meeting held virtually in November 2022.
Hemanext's RBC Processing & Storage System is CE Marked for the processing and storage of leukocyte-reduced RBCs.